Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.39 |
| ▸ | HRH2 | P25021 | 1/20 | 0.39 |
| ▸ | HRH1 | P35367 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | F10 | P00742 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6733747 | 1.00 | HRH3 (0.39) | HRH3HRH2HRH1MAOBF10 | |
| SCHEMBL2210788 | 0.93 | HRH3 (0.40) | HRH3HRH2HRH1MAOBF10 | |
| SCHEMBL2110831 | 0.93 | HRH3 (0.40) | HRH3HRH2HRH1MAOBF10 | |
| SCHEMBL10505714 | 0.93 | HRH3 (0.40) | HRH3HRH2HRH1MAOBF10 | |
| SCHEMBL10505725 | 0.93 | HRH3 (0.40) | HRH3HRH2HRH1MAOBF10 | |
| SCHEMBL855413 | 0.91 | HRH3 (0.36) | HRH3HRH2HRH1MAOB | |
| SCHEMBL11199066 | 0.84 | HRH3 (0.37) | HRH3HRH2HRH1MAOB | |
| SCHEMBL544481 | 0.84 | LTA4H (0.38) | HRH3HRH2HRH1MAOB | |
| SCHEMBL10681465 | 0.84 | LTA4H (0.38) | HRH3HRH2HRH1MAOB | |
| SCHEMBL10504563 | 0.84 | LTA4H (0.38) | HRH3HRH2HRH1MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040058905-A1 | Immunosuppressants; Alzheimer's diseases; central nervous system disorders; strokes | PFIZER INC. | 2004-03-25 | — | — | US | disclosed |
| US-6686357-B1 | BENZIMIDAZOLO-PIPERIDINE COMPOUND | PFIZER, INC. | 2004-02-03 | — | — | US | disclosed |
| US-6509464-B1 | 1-Heteroaryl-pyrrolidine, piperidine, or homopiperidine derivates; nervous system disorder treatment; amidation | PFIZER INC | 2003-01-21 | — | — | US | disclosed |
| US-6495549-B1 | 1-HETEROARYL-PIPERIDINE DERIVATIVES; MODERATING NEURONAL DEGENERATION; PROMOTING NEURONAL REGENERATION AND OUTGROWTH; TREATOG NEUROLOGICAL DISORDERS ARISING FROM NEURODEGENERATIVE DISEASES OR OTHER DISORDERS INVOLVING NERVE DAMAGE | PFIZER INC | 2002-12-17 | — | — | US | disclosed |
| EP-1098894-B1 | FKBP INHIBITORS | PFIZER LTD (GB) | 2002-10-02 | — | — | EP | disclosed |
| EP-1098894-A1 | FKBP INHIBITORS | Pfizer Limited (GB) | 2001-05-16 | — | — | EP | disclosed |
| US-6166011-A | FKBP inhibitors | PFIZER INC (US) | 2000-12-26 | — | — | US | disclosed |
| WO-2000005231-A1 | FKBP INHIBITORS | PFIZER LIMITED (GB) | 2000-02-03 | — | — | WO | disclosed |
| US-5034402-A | Cerebral insufficiency | HOFFMANN-LA ROCHE INC. (US) | 1991-07-23 | — | — | US | disclosed |
| US-4650878-A | CEREBRAL INSUFFICIENCY | HOFFMANN-LA ROCHE INC. (US) | 1987-03-17 | — | — | US | disclosed |
| EP-0071216-B1 | 3-HYDROXYPYRROLIDIN-2-ONE DERIVATIVES, PROCESS AND INTERMEDIATES FOR THEIR PREPARATION AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1986-12-30 | — | — | EP | disclosed |
| US-4476308-A | 1-Pyrrolidine acetamides | HOFFMANN-LA ROCHE INC. (US) | 1984-10-09 | — | — | US | disclosed |
| EP-0071216-A2 | 3-Hydroxypyrrolidin-2-one derivatives, process and intermediates for their preparation and pharmaceutical preparations containing them | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1983-02-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058905-A1 | Immunosuppressants; Alzheimer's diseases; central nervous system disorders; strokes | FKBP1A, FKBP4, FKBP1B | HRH3 4785/4885HRH2 4811/4885HRH1 4734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.